Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 16/20 | 0.49 |
| ▸ | DRD4 | P21917 | 16/20 | 0.49 |
| ▸ | DRD3 | P35462 | 16/20 | 0.49 |
| ▸ | CXCR1 | P25024 | 2/20 | 0.48 |
| ▸ | NOTUM | Q6P988 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13616496 | 0.94 | NOTUM (0.46) | DRD2DRD4DRD3CXCR1NOTUM | |
| SCHEMBL13616569 | 0.90 | DRD2 (0.50) | DRD2DRD4DRD3 | |
| SCHEMBL13616497 | 0.89 | DRD2 (0.62) | DRD2DRD4DRD3 | |
| SCHEMBL13616468 | 0.87 | NOTUM (0.48) | DRD2DRD4DRD3CXCR1NOTUM | |
| SCHEMBL13616564 | 0.84 | DRD2 (0.44) | DRD2DRD4DRD3 | |
| SCHEMBL4343036 | 0.82 | DRD2 (0.55) | DRD2DRD4DRD3CXCR1NOTUM | |
| SCHEMBL6764520 | 0.79 | DRD2 (0.60) | DRD2DRD4DRD3 | |
| SCHEMBL6767504 | 0.78 | DRD2 (0.79) | DRD2DRD4DRD3 | |
| SCHEMBL5477728 | 0.78 | DRD2 (0.54) | DRD2DRD4DRD3CXCR1NOTUM | |
| SCHEMBL6773998 | 0.77 | DRD2 (0.63) | DRD2DRD4DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090275594-A1 | 3-HYDRAZONE PIPERAZINYL RIFAMYCIN DERIVATIVES USEFUL AS ANTIMICROBIAL AGENTS | JANSSEN PHARMACEUTICA NV (BE) | 2009-11-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090275594-A1 | 3-HYDRAZONE PIPERAZINYL RIFAMYCIN DERIVATIVES USEFUL AS ANTIMICROBIAL AGENTS | RIF1, ABCC1, HDAC6 | DRD2 3195/4885DRD4 2082/4885DRD3 1251/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.